Akero Therapeutics
AKRO

$28.12

0.71%

Market Cap: 1.94B

About: Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Employees: 58

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 8 analysts

0

News positive %

of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 4 (+2) [Q1 2024]

71% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 21

64% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 45

34% more capital invested

Capital invested by funds: $1.38B [Q4 2023] → $1.85B (+$468M) [Q1 2024]

10% more funds holding

Funds holding: 156 [Q4 2023] → 171 (+15) [Q1 2024]

0.08% more ownership

Funds ownership: 105.89% [Q4 2023] → 105.97% (+0.08%) [Q1 2024]

24% less call options, than puts

Call options by funds: $15.3M | Put options by funds: $20M

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$30

7%

upside

Avg. target

$45

60%

upside

High target

$56

99%

upside

8 analyst ratings

7 positive

88%

1 neutral

13%

0 negative

0%

HC Wainwright & Co. Ed Arce	78%upside $50	Buy Reiterated	11 Jun 2024
Evercore ISI Group Liisa Bayko	35%upside $38	Outperform Maintained	15 May 2024
Canaccord Genuity Edward Nash	99%upside $56	Buy Maintained	13 May 2024
HC Wainwright & Co. Ed Arce	78%upside $50	Buy Reiterated	13 May 2024
B of A Securities Alexandria Hammond	7%upside $30	Neutral Reinstated	22 Apr 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about AKRO published over the past 30 days

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)

NEW YORK , July 17, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Akero Therapeutics, Inc. (NASDAQ: AKRO) on behalf of the company's shareholders. The investigation seeks to determine whether Akero's directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)

Zacks Investment Research

Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade

Akero Therapeutics (AKRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade

Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for potential violations of the federal securities laws.

Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm

AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.

AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

FINAL AKRO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Akero securities between September 13, 2022 and October 9, 2023, inclusive (the "Class Period").

FINAL AKRO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit!

AKRO Today Is the Last Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit

LOS ANGELES , June 25, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ: AKRO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 13, 2022 and October 9, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before June 25, 2024.

AKRO Today Is the Last Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming June 25, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO) common stock between September 13, 2022 and October 9, 2023, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On October 10, 2023, Akero announced the results of.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO

NEW YORK , June 24, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Akero Therapeutics, Inc. ("Akero" or the "Company") (NASDAQ: AKRO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO

AKRO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKRO

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 and October 9, 2023, both dates inclusive (the “Class Period”), of the important June 25, 2024 lead plaintiff deadline.

AKRO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKRO

Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for potential violations of the federal securities laws.

Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm

See News Rankings